Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Reaffirmed by Cantor Fitzgerald

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports.

A number of other analysts have also recently weighed in on ZVRA. Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Roth Mkm raised their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Monday. Finally, JMP Securities assumed coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Up 0.3 %

Shares of NASDAQ ZVRA opened at $6.94 on Tuesday. Zevra Therapeutics has a 52-week low of $3.89 and a 52-week high of $8.95. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. The company’s 50-day simple moving average is $7.16 and its 200-day simple moving average is $5.75. The firm has a market cap of $290.46 million, a price-to-earnings ratio of -5.14 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. During the same quarter in the previous year, the business posted ($0.15) earnings per share. Equities analysts predict that Zevra Therapeutics will post -1.59 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director John B. Bode acquired 10,000 shares of the company’s stock in a transaction dated Friday, July 12th. The shares were bought at an average price of $5.87 per share, for a total transaction of $58,700.00. Following the acquisition, the director now owns 30,000 shares in the company, valued at approximately $176,100. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders acquired 22,000 shares of company stock worth $140,340. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC bought a new position in shares of Zevra Therapeutics in the fourth quarter valued at $1,755,000. Jacobs Levy Equity Management Inc. grew its position in Zevra Therapeutics by 102.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after buying an additional 17,557 shares in the last quarter. Virtu Financial LLC bought a new stake in Zevra Therapeutics during the fourth quarter worth about $177,000. Focus Financial Network Inc. ADV acquired a new position in Zevra Therapeutics during the fourth quarter valued at approximately $141,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Zevra Therapeutics in the first quarter valued at about $64,000. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.